Decrease of circulating SAA is correlated with reduction of abdominal SAA secretion during weight loss

Rong-Ze Yang, Jacob B Blumenthal, Nicole M Glynn, Mi-Jeong Lee, Andrew P Goldberg, Da-Wei Gong, Alice S Ryan, Rong-Ze Yang, Jacob B Blumenthal, Nicole M Glynn, Mi-Jeong Lee, Andrew P Goldberg, Da-Wei Gong, Alice S Ryan

Abstract

Objective: The study goal was to determine the effect of weight loss (WL) alone and with aerobic exercise (WL + AEX) on serum amyloid A (SAA) levels and adipose SAA secretion from gluteal and abdominal depots.

Methods: Ninety-six overweight or obese postmenopausal women undertook a 6-month WL alone (n = 47) or with AEX training (n = 49) (6 months WL and WL + AEX are considered WL when groups were combined). Their serum SAA levels, body weight, and adipose SAA secretion ex vivo from gluteal and abdominal depot were measured before and after WL interventions.

Results: The participants lost an average of 8% body weight with a 10% decrease of serum SAA. Serum SAA levels remained significantly correlated with body weight before and after WL. However, the changes of serum SAA level did not correlate with changes of body weight. The gluteal adipose tissue secreted ∼50% more SAA than the abdominal tissue, but the changes of abdominal, but not gluteal, SAA secretion correlated (R(2) = 0.19, p < 0.01) with those of serum SAA levels during WL.

Conclusions: No linear correlation between the decrease in systemic SAA and WL was found. There is a depot-dependent difference in adipose SAA secretion and abdominal SAA secretion, which may partially account for the systemic SAA reduction during WL.

Trial registration: ClinicalTrials.gov NCT00882141.

Copyright © 2013 The Obesity Society.

Figures

Figure 1. Change of serum SAA levels…
Figure 1. Change of serum SAA levels and its relationship with BMI/fat mass before and after WL
A. Relationship between BMI and % Fat Mass and Serum SAA pre-WL. Linear correlation analysis of serum SAA levels (μg/ml, log-transformed and presented) with BMI and percentage of fat mass (% of fat mass) pre-WL in 96 overweight or obese postmenopausal women. B. Changes in Body Weight (BW) and SAA after WL and WL+AEX. 47 subjects underwent a WL program and 49 subjects received WL +AEX. SAA levels (μg/ml) and body weight (kg) changes were compared before and after WL (**: p < 0.01, paired t-test) with the mean % reduction of SAA and body weight shown. No difference was detected between WL vs. WL +AEX treatment by two-way ANOVA. C. Relationship between BMI and % Fat Mass and Serum SAA post-WL. Linear and regression analysis of serum SAA levels (log-transformed) with BMI and percentage of fat mass post-WL in the 96 participants.
Figure 1. Change of serum SAA levels…
Figure 1. Change of serum SAA levels and its relationship with BMI/fat mass before and after WL
A. Relationship between BMI and % Fat Mass and Serum SAA pre-WL. Linear correlation analysis of serum SAA levels (μg/ml, log-transformed and presented) with BMI and percentage of fat mass (% of fat mass) pre-WL in 96 overweight or obese postmenopausal women. B. Changes in Body Weight (BW) and SAA after WL and WL+AEX. 47 subjects underwent a WL program and 49 subjects received WL +AEX. SAA levels (μg/ml) and body weight (kg) changes were compared before and after WL (**: p < 0.01, paired t-test) with the mean % reduction of SAA and body weight shown. No difference was detected between WL vs. WL +AEX treatment by two-way ANOVA. C. Relationship between BMI and % Fat Mass and Serum SAA post-WL. Linear and regression analysis of serum SAA levels (log-transformed) with BMI and percentage of fat mass post-WL in the 96 participants.
Figure 1. Change of serum SAA levels…
Figure 1. Change of serum SAA levels and its relationship with BMI/fat mass before and after WL
A. Relationship between BMI and % Fat Mass and Serum SAA pre-WL. Linear correlation analysis of serum SAA levels (μg/ml, log-transformed and presented) with BMI and percentage of fat mass (% of fat mass) pre-WL in 96 overweight or obese postmenopausal women. B. Changes in Body Weight (BW) and SAA after WL and WL+AEX. 47 subjects underwent a WL program and 49 subjects received WL +AEX. SAA levels (μg/ml) and body weight (kg) changes were compared before and after WL (**: p < 0.01, paired t-test) with the mean % reduction of SAA and body weight shown. No difference was detected between WL vs. WL +AEX treatment by two-way ANOVA. C. Relationship between BMI and % Fat Mass and Serum SAA post-WL. Linear and regression analysis of serum SAA levels (log-transformed) with BMI and percentage of fat mass post-WL in the 96 participants.
Figure 2
Figure 2
Relationship between changes in BMI and changes in serum SAA.
Figure 3. Adipose SAA secretion from subcutaneous…
Figure 3. Adipose SAA secretion from subcutaneous abdominal and gluteal depots before and after WL
A. Adipose SAA secretion before and after weight loss. Data were expressed as mean ± SE. **: p < 0.01 between the two depots in pre- or post-WL state. B. Correlation between Abdominal and Gluteal Adipose SAA Secretion. A total of forty-four subjects had fat biopsies at abdominal and gluteal depots before and after WL. SAA secreted ex vivo from the acute adipose tissue culture (ng SAA/g fat tissue/3 hours) were measured in conditioned media. Data were log-transformed for analyses.
Figure 3. Adipose SAA secretion from subcutaneous…
Figure 3. Adipose SAA secretion from subcutaneous abdominal and gluteal depots before and after WL
A. Adipose SAA secretion before and after weight loss. Data were expressed as mean ± SE. **: p < 0.01 between the two depots in pre- or post-WL state. B. Correlation between Abdominal and Gluteal Adipose SAA Secretion. A total of forty-four subjects had fat biopsies at abdominal and gluteal depots before and after WL. SAA secreted ex vivo from the acute adipose tissue culture (ng SAA/g fat tissue/3 hours) were measured in conditioned media. Data were log-transformed for analyses.
Figure 4
Figure 4
Correlation of the change in systemic SAA with the change in adipose SAA secretion from abdominal, but not gluteal, adipose depot during WL.

References

    1. Chen A, Mumick S, Zhang C, Lamb J, Dai H, Weingarth D, Mudgett J, Chen H, MacNeil DJ, Reitman ML, et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res. 2005;13:1311–1320.
    1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830.
    1. Solinas G. Molecular pathways linking metabolic inflammation and thermogenesis. Obes Rev. 2012;13(Suppl 2):69–82.
    1. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res. 2010;107:579–591.
    1. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
    1. Schmidt AM. Insulin resistance and metabolic syndrome: mechanisms and consequences. Arterioscler Thromb Vasc Biol. 2012;32:1753.
    1. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, Lane WS, de Beer FC. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem. 1992;267:3862–3867.
    1. Hatanaka E, Furlaneto CJ, Ribeiro FP, Souza GM, Campa A. Serum amyloid A-induced mRNA expression and release of tumor necrosis factor-alpha (TNF-alpha) in human neutrophils. Immunol Lett. 2004;91:33–37.
    1. Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun. 2000;268:405–408.
    1. Han CY, Subramanian S, Chan CK, Omer M, Chiba T, Wight TN, Chait A. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes. 2007;56:2260–2273.
    1. Dong Z, Wu T, Qin W, An C, Wang Z, Zhang M, Zhang Y, Zhang C, An F. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med. 2011;17:1357–1364.
    1. Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, Campbell KL, Duggan C, Foster-Schubert KE, Kong A, et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res. 2012;72:2314–2326.
    1. O’Brien KD, Brehm BJ, Seeley RJ, Bean J, Wener MH, Daniels S, D’Alessio DA. Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005
    1. Lappalainen T, Kolehmainen M, Schwab U, Pulkkinen L, Laaksonen DE, Rauramaa R, Uusitupa M, Gylling H. Serum concentrations and expressions of serum amyloid A and leptin in adipose tissue are interrelated: the Genobin Study. Eur J Endocrinol. 2008;158:333–341.
    1. Min JL, Nicholson G, Halgrimsdottir I, Almstrup K, Petri A, Barrett A, Travers M, Rayner NW, Magi R, Pettersson FH, et al. Coexpression network analysis in abdominal and gluteal adipose tissue reveals regulatory genetic loci for metabolic syndrome and related phenotypes. PLoS Genet. 2012;8:e1002505.
    1. Berman DM, Nicklas BJ, Rogus EM, Dennis KE, Goldberg AP. Regional differences in adrenoceptor binding and fat cell lipolysis in obese, postmenopausal women. Metabolism. 1998;47:467–473.
    1. Tchoukalova YD, Koutsari C, Karpyak MV, Votruba SB, Wendland E, Jensen MD. Subcutaneous adipocyte size and body fat distribution. Am J Clin Nutr. 2008;87:56–63.
    1. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 2010;34:949–959.
    1. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843.
    1. Ryan AS, Ortmeyer HK, Sorkin JD. Exercise with calorie restriction improves insulin sensitivity and glycogen synthase activity in obese postmenopausal women with impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2012;302:E145–152.
    1. Dowling HJ, Fried SK, Pi-Sunyer FX. Insulin resistance in adipocytes of obese women: effects of body fat distribution and race. Metabolism. 1995;44:987–995.
    1. Russell CD, Petersen RN, Rao SP, Ricci MR, Prasad A, Zhang Y, Brolin RE, Fried SK. Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am J Physiol. 1998;275:E507–515.
    1. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, Snitker S, Horenstein RB, Hull K, Goldberg NH, et al. Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications. PLoS Med. 2006;3:e287.
    1. Sjoholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, Lystig TC, Jennische E, Brandberg J, Torgerson JS, Carlsson B, et al. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab. 2005;90:2233–2239.
    1. Poitou C, Coussieu C, Rouault C, Coupaye M, Cancello R, Bedel JF, Gouillon M, Bouillot JL, Oppert JM, Basdevant A, et al. Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status. Obesity (Silver Spring) 2006;14:309–318.
    1. You T, Disanzo BL, Wang X, Yang R, Gong D. Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis. 2011;10:194.
    1. Karastergiou K, Fried SK, Xie H, Lee MJ, Divoux A, Rosencrantz MA, Chang RJ, Smith SR. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. J Clin Endocrinol Metab. 2013;98:362–371.
    1. Rantalainen M, Herrera BM, Nicholson G, Bowden R, Wills QF, Min JL, Neville MJ, Barrett A, Allen M, Rayner NW, et al. MicroRNA expression in abdominal and gluteal adipose tissue is associated with mRNA expression levels and partly genetically driven. PLoS One. 2011;6:e27338.
    1. Tan GD, Goossens GH, Humphreys SM, Vidal H, Karpe F. Upper and lower body adipose tissue function: a direct comparison of fat mobilization in humans. Obes Res. 2004;12:114–118.
    1. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–523.
    1. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37:381–388.
    1. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7:64–69.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe